BPC-157 is a synthetic peptide also called Body Protection Compound 157 or pentadecapeptide BPC 157. It has been studied mostly in preclinical injury, wound-healing, and musculoskeletal models, with limited human research and no indexed randomized human trials in the supplied retrieval. It is not a growth hormone, and patients should avoid self-treatment or research-chemical sources 1, 2.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →What it is
BPC-157 is a synthetic pentadecapeptide, meaning it is made of 15 amino acids. In the literature, it is described as gastric pentadecapeptide BPC 157 and has been reviewed for possible roles in wound healing, tissue repair, and musculoskeletal injury research 1, 6.
Names: Body Protection Compound 157, PL 14736, and pentadecapeptide BPC 157
You may see BPC-157 written as Body Protection Compound 157, PL 14736, pentadecapeptide BPC 157, or gastric pentadecapeptide BPC 157. These names refer to the same peptide discussed across sports medicine, orthopaedic, and wound-healing reviews 1, 2, 6.
What type of compound is it?
BPC-157 is not a growth hormone, not a GLP-1 medication, and not the same category as peptides used to affect the growth-hormone axis. It is usually discussed as a synthetic, gastric protein-derived peptide with proposed repair-related effects, but the human evidence is still limited 1, 4.
| Name or term | What it means | Why it matters |
|---|---|---|
| BPC-157 | Short name for Body Protection Compound 157 | Most common search and product name |
| Pentadecapeptide BPC 157 | A 15-amino-acid peptide name used in the literature | Helps distinguish it from hormones or larger proteins |
| PL 14736 | Another identifier used for the compound | May appear in patents or research discussions |
| Gastric pentadecapeptide BPC 157 | A literature term tied to its gastric protein-derived origin | Often appears in wound-healing and tissue-repair reviews |
Mechanism of action
The mechanism of BPC-157 in humans is not established. Reviews describe proposed pathways tied to wound repair, blood-vessel signaling, and musculoskeletal healing, but much of that work is preclinical or mechanistic rather than proven in randomized human outcomes 4, 6, 11.
Tissue repair and wound-healing pathways studied in the literature
Wound-healing reviews discuss BPC-157 as a stable gastric pentadecapeptide studied in repair models. These papers describe possible effects on tissue repair biology, but they do not show that BPC-157 reliably improves healing in patients across injury types 6, 1.
Angiogenesis and musculoskeletal healing signals
Angiogenesis means new blood-vessel growth. BPC-157 reviews discuss angiogenic growth factors and lessons from tendon, ligament, muscle, and bone-healing models, but these proposed signals are not the same as proven patient benefit 11, 4.
Why mechanism studies do not prove patient benefit
A mechanism can explain why a compound is worth studying, but it cannot prove that people will heal faster, avoid surgery, or have less pain. Orthopaedic reviews describe BPC-157 as an emerging peptide of interest while also emphasizing that the evidence base is early and limited 2, 5, 9.
Evidence
The assigned evidence grade for BPC-157 is C. That means human research exists in the supplied PubMed retrieval, but none of it is randomized, so the evidence cannot support strong claims about effectiveness or long-term safety 2, 3, 5.
Evidence grade rubric
A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.
Why BPC-157 is graded C
The supplied retrieval lists 55 human PubMed-indexed records for BPC-157 and no randomized trials. One indexed human primary study reported intra-articular injection of BPC 157 for multiple types of knee pain, but a single non-randomized human report cannot establish broad efficacy for tendon injury, ligament injury, muscle strain, wound healing, or recovery 3, 2.
Recent reviews in orthopaedic sports medicine describe BPC-157 and other therapeutic peptides as areas of interest, but they also stress gaps in human evidence, safety, and product quality. Individual results vary, and preclinical findings should not be treated as expected patient outcomes 7, 8, 9, 10.
| Evidence type | What exists in the supplied source set | What it can tell us | What it cannot tell us |
|---|---|---|---|
| Human primary study | One indexed report on intra-articular BPC 157 injection for multiple types of knee pain | Shows that human use has been reported in the literature | Does not prove broad efficacy or long-term safety |
| Registered clinical trials | A recruiting phase 2 hamstring strain trial and an earlier phase 1 safety/pharmacokinetics trial are listed | Shows that formal clinical research has been registered | Does not give results unless results are posted or published |
| Systematic and narrative reviews | Sports medicine and orthopaedic reviews summarize proposed uses and concerns | Help map the research landscape | Cannot replace randomized human trials |
| Animal and mechanism literature | Reviews discuss wound healing, angiogenesis, tendon, ligament, muscle, and bone models | Can suggest pathways worth testing | Cannot prove patient benefit |
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 2019 | Review / secondary | Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing | Cell and tissue research | PMID 30915550 |
| 2025 | Review / secondary | Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review | Pharmaceuticals (Basel, Switzerland) | PMID 40005999 |
| 2025 | Review / secondary | Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review | HSS journal : the musculoskeletal journal of Hospital for Special Surgery | PMID 40756949 |
| 2021 | Primary study | Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain | Alternative therapies in health and medicine | PMID 34324435 |
| 2021 | Review / secondary | Stable Gastric Pentadecapeptide BPC 157 and Wound Healing | Frontiers in pharmacology | PMID 34267654 |
| 2025 | Review / secondary | Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing | Current reviews in musculoskeletal medicine | PMID 40789979 |
| 2026 | Review / secondary | Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians | The American journal of sports medicine | PMID 41476424 |
| 2026 | Review / secondary | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions | Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews | PMID 41490200 |
| 2025 | Review / secondary | Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance? | Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association | PMID 39265666 |
| 2026 | Review / secondary | Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance | Sports medicine (Auckland, N.Z.) | PMID 41966639 |
| 2018 | Review / secondary | BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing | Current pharmaceutical design | PMID 29998800 |
| 2014 | Review / secondary | BPC 157 and blood vessels | Current pharmaceutical design | PMID 23782145 |
| Registration | Phase | Status | Enrolment | Title |
|---|---|---|---|---|
| NCT07437547 | PHASE2 | RECRUITING | 120 | BPC 157 for Acute Hamstring Muscle Strain Repair |
| NCT02637284 | PHASE1 | UNKNOWN | 42 | PCO-02 - Safety and Pharmacokinetics Trial |
| NCT07752381 | NA | COMPLETED | 40 | A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-02.
Reported dosing ranges
There is no standard BPC-157 dose established from the supplied evidence. The retrieved records identify reported routes and registered study designs, but they do not provide a patient dosing protocol that can be generalized safely 3, 13, 14, 15.
| Source | Population or study type | Route or form described | Dose range available from supplied record | How to interpret it |
|---|---|---|---|---|
| Lee E, Padgett B. 2021 | Human primary study on multiple types of knee pain | Intra-articular injection | No dose amount is available from the supplied citation record | A reported route is not a dosing protocol |
| NCT07437547 | Recruiting phase 2 study, n=120, acute hamstring muscle strain repair | BPC-157 study record | No dose amount is available from the supplied registry summary | Trial registration shows study intent, not patient instructions |
| NCT02637284 | Phase 1 safety and pharmacokinetics trial, n=42, status unknown | PCO-02 safety and pharmacokinetics record | No dose amount is available from the supplied registry summary | Safety and pharmacokinetic study details should not be turned into self-dosing advice |
| NCT07752381 | Completed trial, n=40, peptide gummies and markers of inflammation, performance, and recovery | Gummy form described in registry title | No dose amount is available from the supplied registry summary | A product form in a trial title does not establish a BPC-157 dose |
Reported routes in human and trial records
The supplied human and registry records mention intra-articular injection, a phase 1 safety and pharmacokinetics study, a phase 2 hamstring strain study, and a peptide-gummy trial record. These records are useful for tracking research, but they do not support online dosing protocols for self-use 3, 13, 14, 15.
Why online dosing protocols are not medical guidance
Online peptide protocols often present dose numbers without the health screening, diagnosis, product-quality review, or follow-up that clinical care requires. Reviews of approved and unapproved peptide therapies warn that evidence and safety claims can outrun the data, especially in sports medicine and performance settings 8, 9, 10.
Legal status
| Date | Action | What it means | Source | Evidence |
|---|---|---|---|---|
| 2026-07-23 | Advisory committee reportedly voted 8-6-1 in favour of including BPC-157 on the 503A bulk drug substances list | Advisory vote only, as reported. FDA has not added it to the list, and the substance is not FDA-approved. | Healio (2026-07-24) | Reported — no agency record |
| 2026-07-23 | FDA convened the Pharmacy Compounding Advisory Committee to consider seven peptide bulk drug substances for the 503A list | The meeting establishes that these substances were formally considered. It does not change any substance's status. | FDA Advisory Committee Calendar | FDA / Federal Register |
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-02. See the full legal-status tracker for every compound we follow.
Safety
The main safety issue with BPC-157 is uncertainty. Because the supplied evidence includes limited human research and no indexed randomized human trials, long-term risks, rare adverse effects, contraindications, and interaction patterns are not well defined 5, 9.
Why limited human research makes safety uncertain
A small or non-randomized human evidence base can miss uncommon harms. Reviews focused on musculoskeletal healing and athletic performance describe the need for caution with unapproved peptide therapies because safety, efficacy, and quality data are incomplete 5, 9, 10.
Quality risks with non-prescription peptide sellers
Research-chemical vendors are not medical care. Products sold as “research use only” may raise identity, sterility, impurity, storage, and handling concerns, and sports medicine reviews have highlighted quality and oversight problems around injectable peptide therapy 8, 9, 10.
- Identity risk: the vial may not contain what the label says.
- Impurity risk: unwanted byproducts or contaminants may be present.
- Sterility risk: injectable material must be made and handled to avoid infection risk.
- Dosing risk: online protocols may not account for your diagnosis, medications, pregnancy status, surgery plans, or medical conditions.
- Follow-up risk: there may be no clinician tracking side effects or deciding when to stop.
When to talk to a clinician instead of self-experimenting
Talk with a licensed clinician if you have a tendon injury, ligament injury, muscle strain, unexplained pain, a wound that is not healing, a planned procedure, immune problems, cancer history, pregnancy, breastfeeding, or prescription medication use. The reason is simple: the published safety base is not strong enough to make self-experimentation low-risk 5, 9.
Interactions
No well-defined BPC-157 drug-interaction profile is established in the supplied evidence. That is not reassurance; it means interaction studies are limited or not available in the retrieved human evidence set 5, 9.
Why interaction data are limited
Interaction research usually needs controlled human studies that track medications, supplements, lab findings, adverse events, and clinical outcomes. The supplied retrieval does not include randomized human trials for BPC-157, so medication, supplement, and condition interactions remain uncertain 2, 5, 9.
Questions to bring to a licensed clinician
- Could my pain, injury, or wound need imaging, physical therapy, procedure-based care, or urgent evaluation?
- Do any of my medications increase bleeding, infection, immune, or healing risks?
- Do I have a condition that changes wound healing, such as diabetes, vascular disease, autoimmune disease, or immune suppression?
- Could this affect surgery timing, rehab, sports clearance, or return-to-play decisions?
- How would side effects be monitored, and what would be the stop plan?
How to obtain it legally
A safer peptide-therapy process starts with a licensed clinician evaluation, a prescription only when appropriate, and dispensing through a state-licensed pharmacy. Chia does not offer BPC-157; we provide education on it and can discuss clinician-guided options in our current catalog when they fit a patient’s goals.
What a clinician-reviewed process should include
A clinician-reviewed process should include your health history, medications, allergies, pregnancy status, diagnosis, goals, and follow-up plan. If a prescription is appropriate for a treatment, the pharmacy source should be clear, licensed, and accountable for identity, sterility, storage, and labeling.
What a research-chemical vendor is not
A research-chemical vendor is not a clinician, not a diagnosis, not a sterile compounding pharmacy, and not follow-up care. A website selling peptide vials without a medical evaluation cannot assess whether your injury needs a different kind of care or whether your medications and conditions change your risk.
Where Chia fits: education on BPC-157 and clinician-guided alternatives
At Chia, BPC-157 is education-only. We do not prescribe, dispense, compound, or ship BPC-157. For patients interested in clinician-guided longevity care, our current catalog includes Sermorelin, GHK-Cu cream, NAD+, and Glutathione, as well as the Foundation Longevity protocol.
Chia care is 100% online: a short health questionnaire, review by a licensed US provider, prescribing only when clinically appropriate, and home delivery from state-licensed US 503A compounding pharmacies. A prescription is never guaranteed, and compounded drugs are not FDA-approved. If you want to discuss goals with a provider, you can start with our eligibility quiz.
| Path | What it is | Chia availability | Important note |
|---|---|---|---|
| BPC-157 | Synthetic pentadecapeptide studied for possible tissue-repair uses | Not offered by Chia | Education only on this page |
| Sermorelin | Longevity peptide in Chia’s catalog | Injection, nasal spray, and tablets | Requires licensed-provider evaluation |
| GHK-Cu | Peptide-based skin-focused treatment in Chia’s catalog | Cream | Requires licensed-provider evaluation |
| NAD+ | Longevity treatment in Chia’s catalog | Injection and nasal spray | Requires licensed-provider evaluation |
| Glutathione | Longevity treatment in Chia’s catalog | Injection and nasal spray | Requires licensed-provider evaluation |
BPC-157 is proposed to affect tissue-repair and wound-healing pathways, including blood-vessel and musculoskeletal healing signals. In people, the evidence is limited, so it should not be treated as a proven way to heal injuries or wounds.
Do not treat over-the-counter or research-chemical peptide sellers as medical care. A clinician-reviewed process should include evaluation, a prescription when appropriate, and a licensed pharmacy source.
There is no good human evidence showing that BPC-157 works immediately. Injury healing and pain recovery depend on the diagnosis, tissue involved, rehab plan, and other health factors.
No. BPC-157 is a synthetic pentadecapeptide. It is not growth hormone and is not the same as growth-hormone secretagogues such as sermorelin.
BPC-157 is graded C under the rubric used here: human research exists, but none of it is randomized in the supplied PubMed retrieval. That grade describes the quantity and design of evidence, not whether it works or whether it is safe.
The key safety issue is uncertainty. The supplied evidence does not establish a complete side-effect, contraindication, or long-term safety profile in humans.
No standard patient dose can be taken from the supplied evidence. Published and registered records may describe routes or study designs, but they should not be used as self-dosing instructions.
No. Chia does not prescribe, dispense, compound, or ship BPC-157. Chia does offer other clinician-guided longevity treatments in its current catalog, after licensed-provider evaluation when appropriate.
References
- 1.PMID 40005999 [review/secondary] Józwiak M, Bauer M, Kamysz W, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland). 2025.
- 2.PMID 40756949 [review/secondary] Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2025.
- 3.PMID 34324435 [primary study] Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative therapies in health and medicine. 2021.
- 4.PMID 30915550 [review/secondary] Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and tissue research. 2019.
- 5.PMID 40789979 [review/secondary] McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine. 2025.
- 6.PMID 34267654 [review/secondary] Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology. 2021.
- 7.PMID 41490200 [review/secondary] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026.
- 8.PMID 41476424 [review/secondary] Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine. 2026.
- 9.PMID 41966639 [review/secondary] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026.
- 10.PMID 39265666 [review/secondary] DeFoor MT, Dekker TJ. Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2025.
- 11.PMID 29998800 [review/secondary] Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current pharmaceutical design. 2018.
- 12.PMID 42578445 [primary study] Tewari K, Liu TP, Im C, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. The American journal of sports medicine. 2026.
- 13.NCT07437547 [RECRUITING, PHASE2, n=120] BPC 157 for Acute Hamstring Muscle Strain Repair. ClinicalTrials.gov. 2026.
- 14.NCT02637284 [UNKNOWN, PHASE1, n=42] PCO-02 - Safety and Pharmacokinetics Trial. ClinicalTrials.gov. 2016.
- 15.NCT07752381 [COMPLETED, NA, n=40] A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery. ClinicalTrials.gov. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
